by Peter Ciszewski | Feb 2, 2022
Ajai Chari, MD, from the Mount Sinai School of Medicine, discusses next steps for the TRiMM-2 study, which is investigating teclistamab and talquetamab in combination with daratumumab in relapsed/refractory multiple myeloma patients. Results from this study...
by Peter Ciszewski | Jan 28, 2022
Sihoun Hahn, MD, Director of the Wilson Disease Center of Excellence at Seattle Children’s Research Institute, gives an overview of Wilson disease. As Dr. Hahn explains, Wilson disease is a genetic disorder caused by mutations on the ATP7B gene. These mutations...
by Peter Ciszewski | Jan 26, 2022
Paula Ragan, PhD, CEO and President, X4 Pharmaceuticals, discusses data presented at The American Society of Hematology Meeting & Exposition (ASH 2021) using artificial intelligence/machine learning model to estimate the prevalence of WHIM syndrome in the...
by Peter Ciszewski | Jan 26, 2022
Stefan M. Schieke, MD, Assistant Professor of Dermatology at University of Wisconsin-Madison, provides an overview of cutaneous T-cell lymphoma (CTCL). Cutaneous T-cell lymphoma belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative...
by Peter Ciszewski | Jan 25, 2022
Paolo Ghia, MD, PhD, Professor at the Università Vita-Salute San Raffaele, Milan, Italy, discusses the updated, long-term data from the phase 2 CAPTIVATE study. This study evaluated ibrutinib plus venetoclax as a first-line treatment for chronic lymphocytic...
